These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26552477)

  • 21. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.
    Govindan S; Siraganahalli Eswaraiah M; Basavaraj C; Adinarayan M; Sankaran S; Bakre M
    BMC Cancer; 2020 Aug; 20(1):745. PubMed ID: 32778063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
    Astvatsaturyan K; Yue Y; Walts AE; Bose S
    PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel genes associated with lymph node metastasis in triple negative breast cancer.
    Mathe A; Wong-Brown M; Morten B; Forbes JF; Braye SG; Avery-Kiejda KA; Scott RJ
    Sci Rep; 2015 Nov; 5():15832. PubMed ID: 26537449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
    Guiu S; Charon-Barra C; Vernerey D; Fumoleau P; Campone M; Spielmann M; Roché H; Mesleard C; Arnould L; Lemonnier J; Lacroix-Triki M
    Future Oncol; 2015; 11(16):2283-97. PubMed ID: 26260807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence.
    Izumi K; Ito Y; Miyamoto H; Miyoshi Y; Ota J; Moriyama M; Murai T; Hayashi H; Inayama Y; Ohashi K; Yao M; Uemura H
    Oncotarget; 2016 Mar; 7(12):14153-60. PubMed ID: 26885620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer.
    Kim EY; Lee KH; Yun JS; Park YL; Park CH; Do SI; Chae SW
    Int J Clin Exp Pathol; 2017; 10(7):7929-7939. PubMed ID: 31966643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
    Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
    Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
    Kikuchi K; McNamara KM; Miki Y; Moon JY; Choi MH; Omata F; Sakurai M; Onodera Y; Rai Y; Ohi Y; Sagara Y; Miyashita M; Ishida T; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Dec; 166(3):709-723. PubMed ID: 28831645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.
    Zhang L; Fang C; Xu X; Li A; Cai Q; Long X
    Biomed Res Int; 2015; 2015():357485. PubMed ID: 25695063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer.
    Pistelli M; Ballatore Z; Santinelli A; Biscotti T; Piva F; Occhipinti G; Della Mora A; Pagliacci A; Battelli N; Bastianelli L; De Lisa M; Bracci R; Maccaroni E; Berardi R; Cascinu S
    Oncol Rep; 2016 Aug; 36(2):755-62. PubMed ID: 27350136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
    Gasparini P; Fassan M; Cascione L; Guler G; Balci S; Irkkan C; Paisie C; Lovat F; Morrison C; Zhang J; Scarpa A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2014; 9(2):e88525. PubMed ID: 24505496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
    Teoh PY; Tan GC; Mahsin H; Wong YP
    Malays J Pathol; 2019 Aug; 41(2):125-132. PubMed ID: 31427547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance.
    Gong Y; Wei W; Wu Y; Ueno NT; Huo L
    Cancer; 2014 Jun; 120(12):1775-9. PubMed ID: 24634055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
    Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
    Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen Receptor Expression and its Correlation with Other Risk Factors in Triple Negative Breast Cancers: a Report from Western Iran.
    Payandeh M; Shazad B; Madani S; Ramezani M; Sadeghi M
    Asian Pac J Cancer Prev; 2016; 17(7):3321-4. PubMed ID: 27509970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas.
    Shen T; Wei L; Li X; Parwani AV; Li Z
    Hum Pathol; 2021 Oct; 116():73-81. PubMed ID: 34310983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor status of lymph node metastases from prostate cancer.
    Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
    Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.